Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scholz Visit Paves Way For Limited China BioNTech Vaccine Use

Wider Approval To Follow?

Executive Summary

Recent visits by foreign dignitaries and progress with local mRNA vaccines and antivirals appear to be helping some slight relaxations in China's strict COVID policies, but some experts predict it may still take months for further steps.

You may also be interested in...



China Set To Green-Light First mRNA Vaccine

In what appears to be a step towards a gradual shift away from its strict "COVID Zero" policies, China is poised to approve its first mRNA vaccine - in this case developed domestically - and will accelerate the roll-out of COVID-19 vaccinations in general to seniors over 80.

China Eyes New COVID Vaccines As It Inches Towards Reopening

New planned changes around vaccine approvals and other COVID-19 measures signal China is preparing for a gradual reopening amid its strict policies, but the process could take months.

Can First Approval Of China mRNA Vaccine Change 'COVID Zero' Approach?

The first approval of a China-originated mRNA COVID-19 vaccine has come ahead of the key Communist Party Congress and Beijing's next pandemic policy decisions will be closely watched.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147320

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel